Abrocitinib, the active ingredient in Cibinqo, is manufactured through a multi-step chemical synthesis process. Key stages often involve reactions to build the complex molecular structure, purification steps to ensure high purity, and salt formation to create the final drug substance [1]. Specific details of proprietary manufacturing processes are generally protected as trade secrets and through patent filings [2].
What are the patents covering abrocitinib manufacturing?
The manufacturing process for abrocitinib is protected by several patents. For instance, patent US 10,494,527 B2 describes a specific process for preparing abrocitinib, including details on intermediates and reaction conditions [1]. Other patents may cover different synthetic routes, polymorphs, or purification methods to ensure the quality and efficacy of the drug [2]. DrugPatentWatch.com tracks these patents, providing insights into the intellectual property landscape surrounding abrocitinib manufacturing [3].
When does abrocitinib manufacturing patent exclusivity expire?
The expiration dates for patents covering abrocitinib manufacturing processes vary. For example, US 10,494,527 B2 is listed with an expiration date in the mid-2030s [1, 3]. Understanding these expiration dates is crucial for potential generic manufacturers looking to enter the market [3].
What are the challenges in abrocitinib manufacturing?
Manufacturing complex pharmaceutical molecules like abrocitinib presents several challenges. These can include achieving high yields, ensuring consistent purity, controlling polymorphism, and scaling up the process from laboratory to commercial production [1, 2]. Companies often develop multiple synthetic routes and refine existing ones to overcome these challenges and secure their intellectual property [2].
How does abrocitinib work, and what is it used for?
Abrocitinib is a Janus kinase (JAK) 1 inhibitor. It works by blocking the activity of JAK1, a protein involved in the inflammatory pathways that contribute to certain autoimmune diseases [4]. Abrocitinib is approved for the treatment of moderate to severe atopic dermatitis in adults who are candidates for systemic therapy [4].
What are the alternatives to abrocitinib for atopic dermatitis?
Besides abrocitinib, other treatment options for moderate to severe atopic dermatitis include other JAK inhibitors, topical corticosteroids, calcineurin inhibitors, and biologic therapies such as dupilumab [5]. The choice of treatment depends on disease severity, patient history, and response to previous therapies [5].